Ameritas Investment Partners’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Ameritas Investment Partners’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,332	Closed	-$12K	–	3298
2021 Q1	$12K	Hold	2,332	–	–	﹤0.01%	2795
2020 Q4	$29K	Hold	2,332	–	–	﹤0.01%	2299
2020 Q3	$23K	Hold	2,332	–	–	﹤0.01%	2311
2020 Q2	$23K	Buy	2,332 +805	+53%	+$7.72K	﹤0.01%	2304
2020 Q1	$13K	Hold	1,527	–	–	﹤0.01%	2418
2019 Q4	$14K	Hold	1,527	–	–	﹤0.01%	2606
2019 Q3	$9K	Hold	1,527	–	–	﹤0.01%	2797
2019 Q2	$18K	Hold	1,527	–	–	﹤0.01%	2516
2019 Q1	$18K	Hold	1,527	–	–	﹤0.01%	2441
2018 Q4	$19K	Hold	1,527	–	–	﹤0.01%	2379
2018 Q3	$23K	Hold	1,527	–	–	﹤0.01%	2449
2018 Q2	$26K	Hold	1,527	–	–	﹤0.01%	2366
2018 Q1	$35K	Hold	1,527	–	–	﹤0.01%	2127
2017 Q4	$40K	Buy	1,527 +340	+29%	+$6.85K	﹤0.01%	2053
2017 Q3	$18K	Hold	1,187	–	–	﹤0.01%	2493
2017 Q2	$17K	Hold	1,187	–	–	﹤0.01%	2568
2017 Q1	$20K	Buy	+1,187	New	+$14.2K	﹤0.01%	2411

Other funds holding CNCE

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ameritas Investment Partners's CNCE Position: Q2 2021 in Review

Ameritas Investment Partners sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2021, closing a stake of 2,332 shares — an estimated $12K sold.

Ameritas Investment Partners first reported a position in CNCE in Q1 2017 and held it in 17 quarters. The position peaked at $40K in Q4 2017. 79 funds tracked by Wall St. Rank hold CNCE as of Q2 2021.

Ameritas Investment Partners reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
Ameritas Investment Partners sold 2,332 Concert Pharmaceuticals, Inc. shares in Q2 2021, an estimated $12K.
Ameritas Investment Partners first reported a position in Concert Pharmaceuticals, Inc. in Q1 2017 and held it in 17 quarters.
Ameritas Investment Partners's Concert Pharmaceuticals, Inc. position peaked at $40K in Q4 2017.
79 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2021.

Based on Ameritas Investment Partners's 13F filing for Q2 2021, filed 6 Aug 2021.